Trials / Terminated
TerminatedNCT03182257
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
An Open-label, Multi-center, Dose-escalation and Expansion Study to Evaluate the Safety and Efficacy of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with advanced solid tumors, and evaluate efficacy of ONO-7579 in patients with advanced solid tumors harboring NTRK gene fusions.
Detailed description
The trial was designed to be a Phase 1/2 trial, but was terminated without progressing to Phase 2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-7579 | ONO-7579 Tablets |
Timeline
- Start date
- 2017-07-12
- Primary completion
- 2018-01-30
- Completion
- 2018-01-30
- First posted
- 2017-06-09
- Last updated
- 2019-09-13
Locations
5 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03182257. Inclusion in this directory is not an endorsement.